🚀 VC round data is live in beta, check it out!
Autobio Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Autobio Diagnostics and similar public comparables like Carl Zeiss Meditec, Haemonetics, Ambu, MGI Tech and more.
Autobio Diagnostics Overview
About Autobio Diagnostics
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company’s main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
Founded
1999
HQ
Employees
5.8K
Website
Financials (LTM)
EV
$3B
Autobio Diagnostics Financials
Autobio Diagnostics reported last 12-month revenue of $625M.
In the same LTM period, Autobio Diagnostics generated $404M in gross profit and $162M in net income.
Revenue (LTM)
Autobio Diagnostics P&L
In the most recent fiscal year, Autobio Diagnostics reported revenue of $655M and EBITDA of $262M.
Autobio Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $625M | XXX | $655M | XXX | XXX | XXX |
| Gross Profit | $404M | XXX | $429M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | — | XXX | $262M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $162M | XXX | $175M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 27% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Autobio Diagnostics Stock Performance
Autobio Diagnostics has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Autobio Diagnostics' stock price is $5.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAutobio Diagnostics Valuation Multiples
Autobio Diagnostics trades at 4.4x EV/Revenue multiple, and 10.5x EV/EBITDA.
EV / Revenue (LTM)
Autobio Diagnostics Financial Valuation Multiples
As of April 20, 2026, Autobio Diagnostics has market cap of $3B and EV of $3B.
Equity research analysts estimate Autobio Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Autobio Diagnostics has a P/E ratio of 17.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBIT | 15.0x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | 6.4x | XXX | XXX | XXX |
| P/E | 17.6x | XXX | 16.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 29.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Autobio Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Autobio Diagnostics Margins & Growth Rates
Autobio Diagnostics' revenue in the last 12 month grew by 12%.
Autobio Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Autobio Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | (8%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (3%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Autobio Diagnostics Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Autobio Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Carl Zeiss Meditec | XXX | XXX | XXX | XXX | XXX | XXX |
| Haemonetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ambu | XXX | XXX | XXX | XXX | XXX | XXX |
| MGI Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Double Medical Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Autobio Diagnostics M&A Activity
Autobio Diagnostics acquired XXX companies to date.
Last acquisition by Autobio Diagnostics was on XXXXXXXX, XXXXX. Autobio Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Autobio Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAutobio Diagnostics Investment Activity
Autobio Diagnostics invested in XXX companies to date.
Autobio Diagnostics made its latest investment on XXXXXXXX, XXXXX. Autobio Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Autobio Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Autobio Diagnostics
| When was Autobio Diagnostics founded? | Autobio Diagnostics was founded in 1999. |
| Where is Autobio Diagnostics headquartered? | Autobio Diagnostics is headquartered in China. |
| How many employees does Autobio Diagnostics have? | As of today, Autobio Diagnostics has over 5K employees. |
| Is Autobio Diagnostics publicly listed? | Yes, Autobio Diagnostics is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Autobio Diagnostics? | Autobio Diagnostics trades under 603658 ticker. |
| When did Autobio Diagnostics go public? | Autobio Diagnostics went public in 2016. |
| Who are competitors of Autobio Diagnostics? | Autobio Diagnostics main competitors are Carl Zeiss Meditec, Haemonetics, Ambu, MGI Tech. |
| What is the current market cap of Autobio Diagnostics? | Autobio Diagnostics' current market cap is $3B. |
| What is the current revenue of Autobio Diagnostics? | Autobio Diagnostics' last 12 months revenue is $625M. |
| What is the current revenue growth of Autobio Diagnostics? | Autobio Diagnostics revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Autobio Diagnostics? | Current revenue multiple of Autobio Diagnostics is 4.4x. |
| Is Autobio Diagnostics profitable? | Yes, Autobio Diagnostics is net-income-positive (as of the last 12 months). |
| What is the current net income of Autobio Diagnostics? | Autobio Diagnostics' last 12 months net income is $162M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.